ProteoNic

ProteoNic licenses 2G UNic technology platform for production of biologics to FyoniBio

ProteoNic, a leading provider of premium vector technology and services for production of biologics, and FyoniBio, a contract development organization for biopharmaceuticals, have entered into a technology licensing agreement. Under the agreement, FyoniBio gains worldwide, non-exclusive commercial rights for application of ProteoNic techno-logy in its proprietary CHOnamite platform. As a result, FyoniBio’s clients will profit […]

MIC

Microchip Imaging Cytometry set to make quantitative lab testing more economical, easy-to-use, and accessible

Scientific and technical advances in the field of Microchip Imaging Cytometry (MIC) are set to advance quantitative diagnostic testing that may deliver more economical, easy-to-use, and accessible healthcare to the public, according to a new article published in Opto-Electronic Advances [1].

cannabis

Existing drug tests can detect delta-8-THC – the latest cannabis craze

As the cannabis derivative delta-8-THC grows in popularity, it’s important for drug tests to be able to detect and differentiate it from delta-9-THC – the primary psychoactive ingredient in cannabis. Breaking research showcased at the 2022 AACC Annual Scientific Meeting & Clinical Lab Expo demonstrates that common drug testing methods can do just that.

shutterstock 2021617082

Innovative tests may resolve challenges in children’s healthcare

A first-of-its-kind test could make it easier for newborns to get care for spinal muscular atrophy, a common genetic disease that is life-threatening but treatable if caught in time. Findings on this method and a second innovative test that could improve diagnosis of paediatric urinary tract infections (UTIs) were discussed at the 2022 AACC Annual […]

shutterstock 2083276144

New research could reduce healthcare disparities based on race when diagnosing kidney disease

New research shows that removing a race modifier from a formula used to diagnose kidney disease could lead to more equitable care for Black patients. This study and a second that examines how this same diagnostic approach impacts Asian patients was presented at the 2022 AACC Annual Scientific Meeting & Clinical Lab Expo.

AACC logo

Theranos whistleblowers and experts on AI and genomic sequencing draw nearly 17,000 attendees to 2022 AACC Annual Scientific Meeting

AACC welcomed thousands of medical professionals and healthcare leaders to the 2022 AACC Annual Scientific Meeting & Clinical Lab Expo at the McCormick Place Convention Center in Chicago from July 24-28. The meeting featured ground-breaking diagnostic advances that will help solve challenging patient health problems, and affirmed just how essential laboratory medicine professionals are to […]

EUROLabPolaris klein

New automation technologies at the vanguard of IFA diagnostics

EUROIMMUN has been creating innovative solutions for immunofluorescence diagnostics for over thirty years. Continuing this long tradition, the company has over the last year introduced further groundbreaking products to increase the efficiency and standardization of indirect immunofluorescence assay (IFA) analyses. CLI talked to Dr Panagiotis Grypiotis, Head of Product Management Autoimmune Diagnostics, Endocrinology/Biologics and Automation […]

pv system

Setting high standards for a low environmental impact

How we have cut emissions to limit global warming INTEGRA Biosciences is a leading provider of high-quality laboratory tools and consumables for liquid handling and media preparation. Headquartered in Zizers, Switzerland, the company is committed to fulfilling the needs of laboratory professionals in the life sciences industry, and has a strong focus on minimizing its […]

Renegade.bio

INTEGRA Biosciences makes molecular diagnostics accessible to all with automated pipetting

Renegade.bio

INTEGRA Biosciences’ pipetting solutions are being used by renegade.bio to address the urgent need of diagnostic testing for COVID-19 in the San Francisco Bay Area of California, USA. The company carries out huge numbers of SARS-CoV-2 assays each day, and has chosen INTEGRA’s automated adjustable electronic pipettes and pipetting robots to perform PCR assays faster and more cost-effectively, while retaining high degrees of sensitivity and specificity.

Renegade.bio is a public-benefit corporation, and was founded in March 2020 to make SARS-CoV-2 diagnostic testing more accessible to the wider population, supporting health equity goals. When setting up its workflow, the company chose to combine a decentralized approach to sample collection with automation of repetitive liquid handling tasks with INTEGRA pipetting solutions, reducing their costs while greatly increasing productivity and still turning around assay results in as little as 12 hours.

Dr Gabriel Paulino, Co-founder and Vice President of Product Development and Innovation at renegade.bio, commented: “The ASSIST PLUS pipetting robot equipped with a VOYAGER adjustable tip spacing pipette is one of our main automation platforms. This has really helped us to increase our throughput, as the VOYAGER is the only solution that can automatically adjust the distance between the individual tips, allowing us to move samples between our different sample tubes and plates easily. We also use the VIAFLO 96 handheld electronic pipette for assay set-up, as it’s really useful to be able to pipette reagents into every well of a microplate at the same time.”

“We love the user interface of the INTEGRA products. It’s so easy to program the pipettes, and these intuitive tools have made the whole assay process incredibly streamlined. All the pipetting is now automated, which helps to reduce human error and fatigue, and allows us to work around the clock at our maximum capacity of around 2000 tests a day. INTEGRA was definitely the right solution for us, and we’ve recently invested in a MINI 96 portable electronic pipette to further streamline our workflows.”

Termo Fisher Scientific Transcend DSX-1

Thermo Scientific’s new automated dried spot sampling and analysis system saves time, labour and reagent costs

Termo Fisher Scientific Transcend DSX-1

Thermo Fisher Scientific enables clinical research, toxicology and anti-doping laboratories performing dried spot sampling and analysis to utilize a new automated sample prep and ultra-high-performance liquid chromatography (UHPLC) system to improve efficiency, robustness, sensitivity and sample traceability.

The new Thermo Scientific Transcend DSX-1 integrated sample prep and UHPLC system eliminates disc punching typically associated with dried matrix (spot) cards, and optimizes sample extraction and recovery of multiple matrices (e.g., blood, urine, serum and saliva). The new system enables laboratories performing routine analysis of drugs and other compounds to achieve substantial savings on time, labour and reagent costs compared to manual workflows.

Proprietary flow-through desorption with heated capillary eliminates the need for manual, time-consuming extraction protocols and the automatic addition of an internal standard prior to the extraction minimizes matrix interference. Robustness and sensitivity are enhanced through online proprietary sample cleanup and enrichment via Thermo Scientific TurboFlow technology, producing confident results.

“Toxicology laboratories play a crucial role in detecting drug use and misuse in an ongoing struggle to safeguard society against increasing numbers of substances at ever decreasing concentrations. Dried spot analysis has emerged as a key technology in this area, requiring only a small amount of sample and, therefore, minimizing the user impact,” said Brad Hart, senior director, analytical vertical and life science mass spectrometry marketing, Thermo Fisher Scientific. “With the conventional workflow being held back by time-consuming manual procedures, we designed the Transcend DSX-1 system to ensure laboratories are able to effectively increase throughput to meet demand, while still ensuring the integrity and quality of results that are expected.”

Professor Mario Thevis, director for the Center for Preventative Doping Research, German Sport University, Cologne said: “Dried blood spot (DBS) tests have the potential to contribute substantially to an improved anti-doping testing program, today and in the future, supporting the clean athlete as well as the overall doping control analytical strategy. DBS analysis is the latest tool approved by the World Anti-Doping Agency (WADA) and was introduced at this year’s Winter Olympic Games in Beijing, China. In order to accommodate the specific needs associated with DBS analyses, and the considerable number of target analytes, robust, sensitive, programmable and especially automated DBS analytical options will offer critical advantages to anti-doping laboratories.”

The Transcend DSX-1 system is controlled by Thermo Scientific Aria MX software, which streamlines dried spot analysis by fully integrating all aspects of the workflow, such as:

  • Sample card handling
  • LC pump operation and valve switching
  • On-line sample clean-up
  • Liquid chromatography-tandem mass spectrometry methods.

 

Furthermore, the Intelligent Vision Camera ensures data integrity and enables retrospective monitoring by capturing sample traceability, chain of custody and accurate spot recognition.